Pictet
Investor profile
Venture capital
Also recorded as: Pictet Group
Deals
11
distinct rounds
Companies
8
backed
Active span
2006–2025
20 yrs
Total round €
€626M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- Aravis Ventures2
- LODH Immunology Fund2
- Novartis Venture Fund2
- Singular2
- Temasek2
- VI Partners2
- Arab Bank Switzerland1
- BioGeneration Ventures (BGV)1
- Bpifrance1
- BZ Bank1
- Cape Capital1
- Cedar Mundi Ventures1
- Cheng Family1
- CNP Insurance1
- CommerzVentures1
- Committed Capital1
- Compagnie Nationale à Valeur (CNP)1
- Credit Suisse1
- Dawn Biopharma1
- Deutsche Bank1
- DN Capital1
- Export and Investment Fund of Denmark (EIFO)1
- Fabrice Grinda1
- Famille C Venture1
- Forbion1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Azafaros | Netherlands | 1 | €132M |
| NovImmune | Switzerland | 2 | €92M |
| Fairmat | France | 2 | €86M |
| Infogrid | UK | 1 | €83M |
| Antag Therapeutics | Denmark | 1 | €80M |
| Taurus Group | Switzerland | 1 | €61M |
| Le Collectionist | France | 1 | €60M |
| Unique | Switzerland | 2 | €34M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Azafaros | Series B | €132M | 2025-05 |
| Infogrid | Series B | €83M | 2023-04 |
| Antag Therapeutics | Series A | €80M | 2024-12 |
| Taurus Group | Series B | €61M | 2023-02 |
| Le Collectionist | Other | €60M | 2022-12 |
| Fairmat | Series B | €52M | 2025-04 |
| NovImmune | Series C | €50M | 2009-04 |
| NovImmune | Series B | €42M | 2006-05 |
| Fairmat | Other | €34M | 2022-11 |
| Unique | Series A | €29M | 2025-02 |